Second-line therapy of squamous non-small cell lung cancer: an evolving landscape

Area of Science:

• Oncology
• Thoracic Surgery
• Medical Genetics

Background:

• Lung cancer treatment has advanced significantly with targeted therapies and immunotherapy, offering alternatives to chemotherapy.
• Lung squamous cell carcinoma (LSCC) treatment progress lags behind lung adenocarcinoma, with platinum-based chemotherapy as the standard first-line therapy.
• Following disease progression, LSCC patients now have access to novel second-line options like antiangiogenic agents and immune checkpoint inhibitors.

Purpose of the Study:

• To summarize recent advancements in second-line therapy for LSCC.
• To highlight key clinical trial results leading to regulatory approvals for LSCC treatments.
• To discuss the evolving therapeutic landscape and unmet needs in advanced LSCC management.

Main Methods:

• Review of recent clinical trial data for second-line therapies in LSCC.
• Analysis of regulatory approvals based on trial outcomes.
• Expert commentary on current treatment algorithms and future directions.

Main Results:

• Immune checkpoint inhibitors have significantly altered the treatment paradigm for LSCC.
• Approved second-line options include ramucirumab with docetaxel and afatinib.
• There is a lack of predictive biomarkers to guide treatment selection for individual LSCC patients.

Conclusions:

• Immune checkpoint inhibitors represent a major advancement in LSCC treatment.
• Despite progress, targeted agents specific for advanced LSCC are still lacking.
• Biomarker-driven studies are essential for developing personalized treatments for molecularly defined LSCC subgroups.